Ionis’ antisense oligonucleotide technology forms the backbone of three drugs to treat rare diseases. Now, the company is applying the technology to the blood cancer multiple myeloma, and it has positive results in mouse models that it says support a recently launched phase 1 trial.
After selling off its marketed cancer drug and focusing back on its pipeline after the loss of its CEO in 2019, Verastem started 2021 looking for stability in a new chief medical officer.
Haemonetics has moved to acquire Cardiva Medical, maker of bloodstopping and vascular closure systems used during hospital procedures, in a $510 million deal.
Turnstone Biologics has acquired tumor-infiltrating lymphocyte (TIL) startup Myst Therapeutics. The takeover gives Turnstone TIL capabilities put together by an ex-Kite scientist to complement its initial focus on oncolytic viruses.
A phase 2/3 clinical trial of Biohaven Pharmaceutical’s troriluzole in Alzheimer’s disease has missed its co-primary endpoints. Biohaven, which slipped the news out on a federal holiday, is yet to quit on the program, though, pointing to a “nonsignificant numerical difference of a potential benefit” in a 97-subject subgroup to argue troriluzole may have a future in the indication.
Drugs that target the cancer-promoting proteins MDM2 and BET have been tried in acute myeloid leukemia (AML) and haven’t been all that effective on their own. But what if they were combined?
AbbVie and National Institutes of Health (NIH) veteran Francesco Marincola, M.D., will become Gilead’s new head of cell therapy research out of its Kite unit.
Ideaya, Spelman College team up to provide young African American women a steppingstone to biotech careers
When the Biotechnology Innovation Organization (BIO) surveyed its member companies last year, it found they were approaching gender parity but were lagging behind on racial and ethnic diversity. Spelman College and Ideaya Biosciences are taking aim at both through a partnership that will connect the former’s students with internships and other opportunities from the latter.
DALLAS — Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses. In addition, Lantern Pharma has granted the underwriters a 45-day option to purchase up to an additional 642,856 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments. All of the shares of common stock are being offered by Lantern Pharma.
JUPITER, Fla.,– Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme’s distribution partner Regency Lifesciences.